MYGN · Myriad Genetics Inc

$5.32 -0.13 (-2.39%) At close · Jul 28

Market Cap

$502.46M

94.45M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2020

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Mark Capone	CEO	$870,560	—	$4,489,500	—	$184,211	$630,187	$6,174,458
R. Bryan Riggsbee Chief	CEO	$552,796	—	$3,461,500	—	$180,209	$8,836	$4,203,341
Alexander Ford	—	$513,271	—	$1,496,500	—	$150,643	$22,629	$2,183,043
Gary A. King	Former Executive Vice President International Operations Amounts shown reflect the aggregate grant date fair value of restricted stock unit awards granted in each year presented calculated in accordance with FASB ASC Topic 718. Amounts reflect the maximum potential value of each award assuming the highest level of performance associated with the award and are based on the closing price of our common stock on the Nasdaq Global Select Market on the date of grant of the award. For fiscal year 2020, based on the level of achievement of the applicable performance criteria established on the grant date for these restricted stock unit awards, they were awarded at 82 percent of the prior grant level. For Mr. Capone, for fiscal year 2018, the amounts reported in this column reflect the actual cash awards paid under our 2013 Executive Incentive Plan to Mr. Capone pursuant to his annual cash incentive bonus award, calculated based on measurement	$405,725	—	$808,110	—	$108,193	$639,131	$1,961,159
Bernard F. Tobin	Former President of Myriad Autoimmune	$431,295	—	$1,047,550	—	$95,163	$305,037	$1,879,045
Jerry S. Lanchbury	Former Chief Scientific Officer	$493,496	—	$1,197,200	—	$131,599	$6,943	$1,829,238
Nicole Lambert	Chief Operating Officer	$386,859	—	$1,197,200	—	$99,934	$20,713	$1,704,706

Fiscal 2019

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Mark Capone	CEO	$887,000	—	$7,177,500	—	$802,735	$29,449	$8,896,684
Former Chief Operating	Officer	$519,168	—	$2,392,500	—	$293,226	$26,808	$3,231,702
R. Bryan Riggsbee Chief	CEO	$466,650	—	$2,392,500	—	$260,671	$19,162	$3,138,983
Jerry S. Lanchbury	Former Chief Scientific Officer	$508,595	—	$1,914,000	—	$250,228	$12,927	$2,685,750
Bernard F. Tobin	Former President of Myriad Autoimmune	$441,334	—	$1,674,750	—	$199,262	$26,162	$2,341,508
Gary A. King	Former Executive Vice President International Operations Amounts shown reflect the aggregate grant date fair value of restricted stock unit awards granted in each year presented calculated in accordance with FASB ASC Topic 718. Amounts reflect the maximum potential value of each award assuming the highest level of performance associated with the award and are based on the closing price of our common stock on the Nasdaq Global Select Market on the date of grant of the award. For fiscal year 2020, based on the level of achievement of the applicable performance criteria established on the grant date for these restricted stock unit awards, they were awarded at 82 percent of the prior grant level. For Mr. Capone, for fiscal year 2018, the amounts reported in this column reflect the actual cash awards paid under our 2013 Executive Incentive Plan to Mr. Capone pursuant to his annual cash incentive bonus award, calculated based on measurement	$383,294	—	$1,291,950	—	$200,079	$229,832	$2,105,155
Women’s Health	Oncology, and International	$369,169	—	$416,626	—	$194,198	$13,795	$993,788

Fiscal 2018

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Mark Capone	CEO	$852,000	—	$5,374,050	—	$817,920	$10,980	$7,054,950
Former Chief Operating	Officer	$499,200	—	$1,954,200	—	$296,525	$11,020	$2,760,945
R. Bryan Riggsbee Chief	CEO	$432,000	—	$1,954,200	—	$254,016	$5,366	$2,645,582
Jerry S. Lanchbury	Former Chief Scientific Officer	$493,782	—	$1,628,500	—	$244,422	$10,972	$2,377,676
Bernard F. Tobin	Former President of Myriad Autoimmune	$424,360	—	$1,302,800	—	$201,571	$10,950	$1,939,681
Gary A. King	Former Executive Vice President International Operations Amounts shown reflect the aggregate grant date fair value of restricted stock unit awards granted in each year presented calculated in accordance with FASB ASC Topic 718. Amounts reflect the maximum potential value of each award assuming the highest level of performance associated with the award and are based on the closing price of our common stock on the Nasdaq Global Select Market on the date of grant of the award. For fiscal year 2020, based on the level of achievement of the applicable performance criteria established on the grant date for these restricted stock unit awards, they were awarded at 82 percent of the prior grant level. For Mr. Capone, for fiscal year 2018, the amounts reported in this column reflect the actual cash awards paid under our 2013 Executive Incentive Plan to Mr. Capone pursuant to his annual cash incentive bonus award, calculated based on measurement	$389,045	—	$977,100	—	$174,563	$317,475	$1,858,183
Women’s Health	Oncology, and International	$319,072	—	$278,474	—	$94,860	$10,863	$703,269

Executive changes

Person	Role	Change	Effective	Filed
Daniel M. Skovronsky M.D., Ph.D.	director	Resigned	2026-06-17	2026-06-23
Lee N. Newcomer, M.D	Class III director	Appointed	2026-06-04	2026-06-04
Rashmi Kumar	Class III director	Appointed	2026-06-04	2026-06-04
Paul M. Bisaro	Class III director	Appointed	2026-06-04	2026-06-04

Key facts CIK 899923 CUSIP 62855J104 13F (30d) 29 filings 29 filers Visit website Investor relations